-
Media ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Media ReleaseNovartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²
-
Media ReleaseNovartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²
-
Media ReleaseNovartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²
-
Media ReleaseNovartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
-
Media ReleaseNovartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
-
Media ReleaseNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
-
Media ReleaseNovartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
-
Story
The future of medicine is here -
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
-
Media ReleaseNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients